Showing results (601-610 of 673) with videos related to
Sort By:
Pageof 68
HIV Clinical Trials|May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PIJose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.HIV Clinical Trials|June 3, 2009
Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active antiretroviral therapy: analyses of six clinical studiesBelinda Ha, Qiming M Liao, Lynn P Dix, et al.HIV Clinical Trials|June 3, 2009
Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeksF Pulido, V Estrada, J G Baril, et al.HIV Clinical Trials|June 3, 2009
Geographic and temporal trends of transmitted HIV-1 drug resistance among antiretroviral-naïve subjects screening for two clinical trials in North America and Western EuropeSibtain Rahim, Linda M Fredrick, Barbara A da Silva, et al.HIV Clinical Trials|June 3, 2009
Hot topics in HIV and hepatitis coinfection: noninvasive diagnosis of liver disease, liver transplantation, and new drugs for treatment of hepatitis coinfectionJürgen Kurt RockstrohHIV Clinical Trials|August 30, 2008
Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once dailyRichard Elion, Calvin Cohen, Douglas Ward, et al.HIV Clinical Trials|August 30, 2008
"White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patientsThomas J Podsadecki, Bernard C Vrijens, Eric P Tousset, et al.HIV Clinical Trials|March 15, 2005
Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 populationNehal Mehta, Muredach ReillyHIV Clinical Trials|March 15, 2005
The 2004 International AIDS Conference and how to globally counter HIV/AIDSVincent IdemyorHIV Clinical Trials|October 25, 2007
Randomized controlled trial of once-daily tenofovir, lamivudine, and lopinavir/ritonavir versus remaining on the same regimen in virologically suppressed HIV-infected patients on their first PI-containing HAART regimenMona R Loutfy, Nabil Ackad, Tony Antoniou, et al.Pageof 68